# KANDLELIT-007 (NCT07190248)

> A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07190248
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non-small Cell Lung Cancer
- Interventions: Calderasib; Pembrolizumab (+) Berahyaluronidase alfa; Pemetrexed; Cisplatin; Carboplatin
- Enrollment: 675
- Primary outcome: Progression Free Survival (PFS) in Participants with Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=kandlelit-007-nct07190248